{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-061538","form_type":"8-K","ticker":null,"cik":"0001851194","company_name":"Ventyx Biosciences, Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.014933+00:00","generated_at":"2026-06-05T01:55:38.108709+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ventyx raises $100M in private placement; discloses securities class action lawsuit","bullets":["Sold 11,174,000 shares at $8.95/share for gross proceeds ~$100M; led by Farallon, Cormorant, Deerfield, Redmile, Surveyor.","Net proceeds to fund VTX3232, VTX2735, VTX002 clinical development and preclinical programs; cash runway extended into at least 2H 2026.","Private placement expected to close on March 11, 2024, subject to customary conditions.","Securities class action filed Mar 1 alleges misleading statements on VTX958 Phase 2 trial; company believes lawsuit without merit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-061538","json":"https://secwatch.observer/filing/0001193125-24-061538.json","markdown":"https://secwatch.observer/filing/0001193125-24-061538.md","text":"https://secwatch.observer/filing/0001193125-24-061538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/0001193125-24-061538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/d765460d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:55:38.108709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"705e368358b38afd14fee314f7639302d16d92c2","claim":"Ventyx Biosciences, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2024-03-06).","evidence_excerpt":"In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated March 6, 2024 (the “ Registration Rights Agreement ”), providing for the registration for resale of the Shares that are not then registered on an effective registration statement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/0001193125-24-061538-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the Purchasers"},{"label":"Effective","value":"2024-03-06"}],"fact_type":"material_agreement"},{"claim_id":"c179407c1862c5aa49e8a55d0f8deabaa641d957","claim":"Ventyx Biosciences, Inc. entered into Stock Purchase Agreement with certain qualified institutional buyers and institutional accredited investors valued at approximately $100.0 million (effective 2024-03-06).","evidence_excerpt":"On March 6, 2024, Ventyx Biosciences, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain qualified institutional buyers and institutional accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851194/000119312524061538/0001193125-24-061538-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain qualified institutional buyers and institutional accredited investors"},{"label":"Value","value":"approximately $100.0 million"},{"label":"Effective","value":"2024-03-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}